Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength - Wikidata - awgldk - TriplyDB

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

http://www.wikidata.org/entity/Q28274891

about

Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways Bone repair with skeletal stem cells: rationale, progress to date and clinical application Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges Sclerostin Inhibition in the Management of Osteoporosis From disease to treatment: from rare skeletal disorders to treatments for osteoporosis Emerging Therapies for Osteoporosis Mechanism and Treatment Strategy of Osteoporosis after Transplantation Osteocytes: master orchestrators of bone Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis Parathyroid Hormone Induces Bone Cell Motility and Loss of Mature Osteocyte Phenotype through L-Calcium Channel Dependent and Independent Mechanisms Novel approaches for two and three dimensional multiplexed imaging of osteocytes.LRP5 and LRP6 in development and disease WNT signaling in bone homeostasis and disease: from human mutations to treatments Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody Regulation of Wnt/β-catenin signaling within and from osteocytes Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.Profile of romosozumab and its potential in the management of osteoporosis.Pharmacological management of osteogenesis.Wnt signaling and osteoporosis.Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis.Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.Inhibitors of sclerostin: emerging concepts.Association study of polymorphisms in the SOST gene region and parameters of bone strength and body composition in both young and elderly men: data from the Odense Androgen Study.Emerging therapeutic opportunities for skeletal restoration.Sclerostin.Erythroid promoter confines FGF2 expression to the marrow after hematopoietic stem cell gene therapy and leads to enhanced endosteal bone formation.Early brain vulnerability in Wolfram syndrome.The neurobiology of skeletal pain The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors A roadmap to the brittle bones of cystic fibrosis.Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels Romosozumab for the treatment of osteoporosis.Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.Sclerostin and Dickkopf-1 in renal osteodystrophy.Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment Gremlin1 is required for skeletal development and postnatal skeletal homeostasis

P2860

Q24621990-19E8AFA8-50A0-4463-918E-1C64982F63C7 Q26744340-F9FE7902-3C50-441C-A40A-11C3CE1A42A7 Q26744599-358D6CD1-3AD8-49A1-9A65-064C9C3CB17F Q26750713-20D1B400-F5F2-41DE-AC84-69EA392CF2E2 Q26764854-B1A3149D-6169-4863-B2C7-097C445E3D8E Q26782109-3F90D623-0668-4515-9B78-ED24B81B2982 Q26798296-BE6637B0-2160-422B-8B6F-EF54E942757A Q27022407-35DE556C-A8C4-4A7E-9C7D-67F31C41B5EB Q27022580-0A35B6C1-F965-450A-B5A7-0FD764188690 Q27308118-039B6F8E-EDC7-46CC-9E0B-143D44FB59C5 Q27324936-97DB01D3-56EF-472F-BE46-4561505AE08B Q27692072-8F60E6FA-1181-4069-94B3-3F74AE4F1712 Q28285090-7A6E1594-0196-44C4-AD88-DBDA3BF2C523 Q28286616-527ED583-FFE9-43FA-91F8-B4CEAEDE0930 Q28286814-D08A1418-7A5D-4B8A-BB38-4A20D048F3D3 Q28535490-C0798AED-8DD9-4965-9C01-98DE2F89F48F Q28584092-D84F0C23-9A55-4326-8220-782EFD858B6F Q30713102-2C2F1E8D-D637-43E1-BD50-3DE68D85FD5B Q33564617-6CC889F6-F1CE-477F-A5F5-92F307EC8F27 Q33596475-422021A0-7FCB-4BD6-B0E3-44691B7992BE Q33729548-6D52B013-883F-4A8D-8319-8977DA0EEC3B Q33784662-9ED71E9E-7836-4A5C-9696-B7B684DEDF08 Q33825376-9A41AD39-9B06-40DB-8B48-51E8EF2DF065 Q33835723-CB6662A1-B4B7-4AF9-B28E-8B01DE0528B2 Q34036439-C86115B0-1F83-4F0C-A1C5-61DCBBB6166F Q34069470-F29DA547-F3D6-4275-BB02-C0C1C3D600E1 Q34072806-D632D86F-542A-46F9-9C3D-2D725E0F3FA3 Q34161867-E3C8264E-3512-4181-80CC-8582E7CEB860 Q34211729-95065436-071D-483C-8D1F-23A4971381DF Q34281991-237D9E7C-EE2D-4868-BD6E-E34EF2FBD97F Q34336601-DEC7D553-D072-4191-B8CB-013904A2BBB0 Q34402192-93C9858C-7C25-4320-AD86-3400BC9792D1 Q34428195-2E91023A-41AD-4CB7-9229-2AC9FAB586A4 Q34442832-4CECC052-11C8-437B-9AEC-05F789AA7EF9 Q34661015-3042DBA6-3618-4F7A-A3EA-848DC6B4B5E2 Q34680463-F81CF141-B511-42FD-9B41-A46ADA2D4919 Q34701183-D305E245-A73A-4F9D-B832-918248C0CE1D Q34751932-299BB0C1-D197-4969-A6CA-501683A4E09E Q34759279-7B537002-DABD-42AE-9655-D5508DD3D5B0 Q35093489-D9F30BAC-B368-4C41-A346-E44F449F777D

P2860

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

http://www.wikidata.org/entity/Q28274891

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Two doses of sclerostin antibo ...... ral density, and bone strength

@ast

Two doses of sclerostin antibo ...... ral density, and bone strength

@en

Two doses of sclerostin antibo ...... ral density, and bone strength

@nl

type

label

Two doses of sclerostin antibo ...... ral density, and bone strength

@ast

Two doses of sclerostin antibo ...... ral density, and bone strength

@en

Two doses of sclerostin antibo ...... ral density, and bone strength

@nl

prefLabel

Two doses of sclerostin antibo ...... ral density, and bone strength

@ast

Two doses of sclerostin antibo ...... ral density, and bone strength

@en

Two doses of sclerostin antibo ...... ral density, and bone strength

@nl

P1433

Q28274891-C21C7887-CEB9-4BB5-B974-C52066B2A421

P1476

Q28274891-EB447943-63D9-40F2-930D-09E9FC9C4EEC

P2093

Q28274891-065DA884-FDEC-414E-8FC9-2C03BF96F226

Q28274891-08BF6723-DD19-4734-9153-4F2C8C9FE691

Q28274891-33E3E725-0F08-4AD9-BA4B-E9F84B887A11

Q28274891-4013ACDC-C7EE-436D-8701-8CD461D8BA4E

Q28274891-57332150-8542-4652-B536-5F3EA6FFEC09

Q28274891-5AB6E1D0-B158-46BE-8801-C1BACA801265

Q28274891-5E30FE09-AD39-44D1-B486-FDD0EC84937C

Q28274891-6978C033-DEA1-4C6C-928F-EBF0E6ADB8E0

Q28274891-6A83BABC-77ED-49DD-93C4-F0E3BC18FA59

Q28274891-6D40372C-F959-4774-B743-B4D32DE3EDAA

P304

Q28274891-06E68635-D914-46E4-AF1F-1CCD3BF73284

P31

Q28274891-E3D900A3-1D8C-4148-9FD6-5866063007B4

P3181

Q28274891-5C4A700D-05F8-4C20-A938-7665C9691746

P356

Q28274891-8D5DBF37-446F-46CE-9234-9DBE55549E7B

P407

Q28274891-F51416CC-E713-430F-8FF3-5216DB409CA8

P433

Q28274891-26C2A735-F451-4453-A423-A82468D969FC

P478

Q28274891-31F6989D-D740-4A9C-98AE-82C2E213C1CF

P577

Q28274891-77B2F7AD-B467-4FCF-BC0E-85F1B3983D9F

P5875

Q28274891-C4CC8877-5256-4299-9076-0E09EB3AEE21

P698

Q28274891-A03444E4-CBD8-461A-801A-019EED23C502

P921

Q28274891-E62437A8-D3F1-46E6-9151-24B8AA759645

P3181

P356

P1433

Journal of Bone and Mineral Research

P1476

Two doses of sclerostin antibo ...... ral density, and bone strength

@en

P2093

Adrian R Moore

http://www.w3.org/2001/XMLSchema#string

Alistair J Henry

http://www.w3.org/2001/XMLSchema#string

Andrew G Popplewell

http://www.w3.org/2001/XMLSchema#string

Barbara Tipton

http://www.w3.org/2001/XMLSchema#string

Brian Stouch

http://www.w3.org/2001/XMLSchema#string

Chris Paszty

http://www.w3.org/2001/XMLSchema#string

Daniel J Lightwood

http://www.w3.org/2001/XMLSchema#string

David L Lacey

http://www.w3.org/2001/XMLSchema#string

Fay Vlasseros

http://www.w3.org/2001/XMLSchema#string

George Doellgast

http://www.w3.org/2001/XMLSchema#string

P304

948-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1230184

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/JBMR.14

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41722737

http://www.w3.org/2001/XMLSchema#string

P698

20200929

http://www.w3.org/2001/XMLSchema#string

P921